Literature DB >> 33706781

Next-generation sequencing facilitates differentiating between multiple primary lung cancer and intrapulmonary metastasis: a case series.

Changjiang Liu1, Chengang Liu1, Xiao Zou2, Lin Shao2, Ying Sun2, Yang Guo3.   

Abstract

BACKGROUND: In lung cancer management, differential diagnosis between multiple primary lung cancer (MPLC) and intrapulmonary metastasis (IMP) is a critical point that is of direct therapeutic and clinical importance. However, this process often suffers from absence of a gold standard, resulting in equivocal cases. Herein, we present a series of three cases, in which genomic alteration patterns revealed by next-generation sequencing (NGS) facilitated the differential diagnosis between MPLC and IMP. CASE
PRESENTATION: Case 1 was a 57-year-old female with two separate lesions in the upper lobe and the lower lobe of left lung, which were both histopathologically determined as T2aN0M0 adenocarcinomas. NGS identified an EGFR L858R in one lesion and an EGFR 20 exon insertion in the other one, suggestive of double primary malignancies. The patient underwent wedge resections and received an adjuvant treatment of icotinib and chemotherapy. She had a disease-free survival (DFS) of 19 months and counting. Case 2 was a 55-year-old female with multiple small lesions in both lungs. Histopathological examinations of resected lesions from right upper lobe revealed three subtypes: atypical adenomatous hyperplasia of alveolar epithelium, adenocarcinomas in situ and minimally invasive adenocarcinoma. NGS identified two different BRAF driver mutations G466E and V600_K601delinsE in two lesions of adenocarcinoma in situ, and a BRAF K601E in a lesion of minimally invasive adenocarcinoma. Case 3, a 68-year-old male, had the right upper lobe lesion histophathologically classified as a stage T3NxM0 mixed adenoneuroendocrine carcinoma and the left upper lobe lesion as a stage T1aN0M0 adenocarcinoma. NGS performed with different loci of surgical tissues revealed a rare sensitizing EGFR mutation G719A shared by the right upper lobe lesion and lymph node, and two EGFR mutations L861Q and G719S in left upper lobe lesion. The patient received icotinib treatment postoperatively and achieved a stable disease with a progression-free survival of 5 months.
CONCLUSION: Our cases provide evidence for utility of NGS in facilitating diagnosis and treatment decisions.

Entities:  

Keywords:  Intrapulmonary metastasis; Multiple primary lung cancer; Multiple pulmonary nodules; Next-generation sequencing; case report

Year:  2021        PMID: 33706781      PMCID: PMC7953741          DOI: 10.1186/s13000-021-01083-6

Source DB:  PubMed          Journal:  Diagn Pathol        ISSN: 1746-1596            Impact factor:   2.644


  10 in total

1.  Multiple primary cancers or multiple metastases, that is the question.

Authors:  Hisao Asamura
Journal:  J Thorac Oncol       Date:  2010-07       Impact factor: 15.609

2.  Pathologists' staging of multiple foci of lung cancer: poor concordance in absence of dramatic histologic or molecular differences.

Authors:  Robert J Homer
Journal:  Am J Clin Pathol       Date:  2015-05       Impact factor: 2.493

3.  Multifocal lung cancers--clonality vs field cancerization and does it matter?

Authors:  Adi F Gazdar; John D Minna
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

4.  Heterogeneous distribution of EGFR mutations is extremely rare in lung adenocarcinoma.

Authors:  Yasushi Yatabe; Keitaro Matsuo; Tetsuya Mitsudomi
Journal:  J Clin Oncol       Date:  2011-07-05       Impact factor: 44.544

Review 5.  Multiple primary lung cancer: a rising challenge.

Authors:  Chen Chen; Xiaojie Huang; Muyun Peng; Wenliang Liu; Fenglei Yu; Xiang Wang
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

6.  Multiple primary lung cancers.

Authors:  N Martini; M R Melamed
Journal:  J Thorac Cardiovasc Surg       Date:  1975-10       Impact factor: 5.209

7.  Proposal for a Combined Histomolecular Algorithm to Distinguish Multiple Primary Adenocarcinomas from Intrapulmonary Metastasis in Patients with Multiple Lung Tumors.

Authors:  Audrey Mansuet-Lupo; Marc Barritault; Marco Alifano; Aurélie Janet-Vendroux; Makmoud Zarmaev; Jérôme Biton; Yoan Velut; Christine Le Hay; Isabelle Cremer; Jean-François Régnard; Ludovic Fournel; Bastien Rance; Marie Wislez; Pierre Laurent-Puig; Ronald Herbst; Diane Damotte; Hélène Blons
Journal:  J Thorac Oncol       Date:  2019-02-02       Impact factor: 15.609

Review 8.  Histopathologic and molecular approach to staging of multiple lung nodules.

Authors:  Frank Schneider; Sanja Dacic
Journal:  Transl Lung Cancer Res       Date:  2017-10

9.  Evidence for common clonal origin of multifocal lung cancers.

Authors:  Xiaoyan Wang; Mingsheng Wang; Gregory T MacLennan; Fadi W Abdul-Karim; John N Eble; Timothy D Jones; Felix Olobatuyi; Rosana Eisenberg; Oscar W Cummings; Shaobo Zhang; Antonio Lopez-Beltran; Rodolfo Montironi; Suqin Zheng; Haiqun Lin; Darrell D Davidson; Liang Cheng
Journal:  J Natl Cancer Inst       Date:  2009-04-07       Impact factor: 13.506

Review 10.  Mutation status concordance between primary lesions and metastatic sites of advanced non-small-cell lung cancer and the impact of mutation testing methodologies: a literature review.

Authors:  James Sherwood; Simon Dearden; Marianne Ratcliffe; Jill Walker
Journal:  J Exp Clin Cancer Res       Date:  2015-09-04
  10 in total
  2 in total

1.  The High Proportion of Discordant EGFR Mutations among Multiple Lung Tumors.

Authors:  Hyunwoo Lee; Jin Hee Park; Joungho Han; Young Mog Shim; Jhingook Kim; Yong Soo Choi; Hong Kwan Kim; Jong Ho Cho; Yoon-La Choi; Wan-Seop Kim
Journal:  Cancers (Basel)       Date:  2022-06-18       Impact factor: 6.575

2.  EGFR-dependent mechanisms of resistance to osimertinib determined by ctDNA NGS analysis identify patients with better outcome.

Authors:  Julie A Vendrell; Xavier Quantin; Audrey Aussel; Isabelle Solassol; Isabelle Serre; Jérôme Solassol
Journal:  Transl Lung Cancer Res       Date:  2021-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.